AJANTA PHARMA LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,399 INR | -1.60% |
|
+1.22% | +15.01% |
| May. 03 | INDIA STOCKS-India's Nifty 50 slips from record high as IT stocks weigh | RE |
| May. 02 | Ajanta Pharma's Consolidated Profit Nearly Doubles in Fiscal Q4 | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 | 42.09B 504M | Sales 2025 * | 47.29B 566M | Capitalization | 305B 3.65B |
|---|---|---|---|---|---|
| Net income 2024 | 8.16B 97.74M | Net income 2025 * | 9.46B 113M | EV / Sales 2024 | 6.67 x |
| Net cash position 2024 * | 7.97B 95.45M | Net cash position 2025 * | 8.39B 100M | EV / Sales 2025 * | 6.26 x |
| P/E ratio 2024 |
34.4
x | P/E ratio 2025 * |
32.7
x | Employees | 7,713 |
| Yield 2024 * |
0.83% | Yield 2025 * |
0.74% | Free-Float | 50.31% |
More Fundamentals
* Assessed data
More news
Latest transcript on Ajanta Pharma Limited
| 1 day | -1.32% | ||
| 1 week | +1.62% | ||
| Current month | +8.60% | ||
| 1 month | +13.61% | ||
| 3 months | +11.74% | ||
| 6 months | +23.43% | ||
| Current year | +15.47% |
1 week
2 350.70
2 458.95
1 month
2 051.602 540.00
Current year
1 998.352 540.00
1 year
1 260.102 540.00
3 years
1 061.772 540.00
5 years
550.002 540.00
10 years
265.362 540.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 98-12-31 | |
| Chief Executive Officer | 52 | 95-12-31 | |
| Director of Finance/CFO | 59 | 98-04-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 52 | 95-12-31 | |
| Chairman | 77 | 79-12-30 | |
| Director/Board Member | 78 | 08-10-19 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 112 M€ | +4.91% | - | |
| 0.00% | 34 M€ | +3.53% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-15 | 2,399 | -1.60% | 260 523 |
| 24-05-14 | 2,438 | +2.44% | 114,737 |
| 24-05-13 | 2,380 | +0.12% | 64,649 |
| 24-05-10 | 2,377 | -1.34% | 135,221 |
| 24-05-09 | 2,410 | +1.77% | 136,168 |
Delayed Quote NSE India S.E., May 15, 2024 at 03:39 am EDT
More quotes
Ajanta Pharma Limited is an India-based specialty pharmaceutical company. The Company provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. The Company is engaged in the manufacturing and sale of branded generic and generic pharmaceutical products. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its branded generics business is spread across India, the rest of Asia, and Africa. Its business also consists of two verticals: United States generics and institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). The Company's cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin.
Sector
Pharmaceuticals
Calendar
2024-07-24
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2,438
INR
Average target price
2,440
INR
Spread / Average Target
+0.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.47% | 3.65B | |
| +20.92% | 44.4B | |
| +24.60% | 23.03B | |
| +18.00% | 15.14B | |
| +13.18% | 13.12B | |
| +44.42% | 11.85B | |
| -8.33% | 6.99B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +12.22% | 5.52B |
- Stock Market
- Equities
- AJANTPHARM Stock